within Pharmacolibrary.Drugs.ATC.M;

model M01AE12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 2.3333333333333336e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014333333333333331,
    Tlag           = 30.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AE12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class used for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. It is approved for use in several countries and works primarily by inhibiting prostaglandin synthesis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult healthy volunteers and arthritis patients after oral administration.</p><h4>References</h4><ol><li><p>Davies, NM (1998). Clinical pharmacokinetics of oxaprozin. <i>Clinical pharmacokinetics</i> 35(6) 425–436. DOI:<a href=\"https://doi.org/10.2165/00003088-199835060-00002\">10.2165/00003088-199835060-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9884815/\">https://pubmed.ncbi.nlm.nih.gov/9884815</a></p></li><li><p>Yin, F, et al., &amp; Chen, Z (2022). Development and In vitro and In vivo Evaluations of a Microemulsion Formulation for the Oral Delivery of Oxaprozin. <i>Current drug delivery</i> 19(3) 347–356. DOI:<a href=\"https://doi.org/10.2174/1567201818666210914092745\">10.2174/1567201818666210914092745</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34521326/\">https://pubmed.ncbi.nlm.nih.gov/34521326</a></p></li><li><p>Greenblatt, DJ, et al., &amp; Shader, RI (1985). Oxaprozin pharmacokinetics in the elderly. <i>British journal of clinical pharmacology</i> 19(3) 373–378. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1985.tb02656.x\">10.1111/j.1365-2125.1985.tb02656.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3986088/\">https://pubmed.ncbi.nlm.nih.gov/3986088</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AE12;
